FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011841487> ?p ?o ?g. }

• W2011841487 abstract "The poor prognosis of patients with drug resistant ovarian cancer and the lack of targeted therapy have raised the need for alternative treatments. Albendazole (ABZ) is an anti-parasite compound capable of impairing microtubule formation. We hypothesized that ABZ could be repurposed as a potential anti-angiogenic drug due to its potent inhibition of vascular endothelial growth factor (VEGF) in ovarian cancer with ascites. However, the poor aqueous solubility of ABZ limits its potential for cancer therapy. In this study, we have assembled ABZ with bovine serum albumin into nanoparticles with a size range of 7–10 nm (BSA-ABZ) and 200–250 nm (Nab-ABZ). We further examined the anticancer effects of ABZ carrying nanoparticles in ovarian cancer cells, in both in vitro and in vivo models. Drug release studies demonstrated that about 93% of ABZ was released from BSA-ABZ 10 nm in comparison to 83% from Nab-ABZ 200 nm at pH 7.4 in 8 days. In vitro cell proliferation studies showed that the BSA-ABZ 10 nm exhibited the highest killing efficacy of ovarian cancer cells with surprisingly least toxicity to healthy ovarian epithelial cells. Confocal microscopy and fluorescence activated cell sorting analysis (FACS) revealed more efficient internalization of the BSA-ABZ 10 nm by cancer cells. For in vivo studies, we examined the tumor growth, ascites formation and the expression of VEGF and secreted protein acidic and rich in cysteine (SPARC) in tumor samples and only VEGF in plasma samples. The BSA-ABZ 10 nm reduced the tumor burden significantly (p < 0.02) at a much lower drug dose (10 μg/ml) compare to free drug. Both formulations were capable of suppressing the ascites volume significantly (p < 0.05) and reducing the number of ascites cells. The expression of VEGF and SPARC was also reduced, which indicates the underlying therapeutic mechanism of the ABZ. Our data suggest that the BSA-ABZ may hold promise for the treatment and control of progression of ovarian cancer with ascites. However further studies are required to examine the efficacy of both the formulations in aggressive models of recurrent ovarian cancer with respect to particle size and dosing parameters." @default.
• W2011841487 created "2016-06-24" @default.
• W2011841487 creator A5016059121 @default.
• W2011841487 creator A5039142646 @default.
• W2011841487 creator A5062094407 @default.
• W2011841487 creator A5083810235 @default.
• W2011841487 creator A5086401476 @default.
• W2011841487 date "2015-03-25" @default.
• W2011841487 modified "2023-10-14" @default.
• W2011841487 title "Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model" @default.
• W2011841487 cites W1664986234 @default.
• W2011841487 cites W1964660643 @default.
• W2011841487 cites W1965097716 @default.
• W2011841487 cites W1972739162 @default.
• W2011841487 cites W1973514430 @default.
• W2011841487 cites W1975088956 @default.
• W2011841487 cites W1977601636 @default.
• W2011841487 cites W1979129848 @default.
• W2011841487 cites W1981147276 @default.
• W2011841487 cites W1985635833 @default.
• W2011841487 cites W1989353157 @default.
• W2011841487 cites W1992292337 @default.
• W2011841487 cites W1994062040 @default.
• W2011841487 cites W2002516695 @default.
• W2011841487 cites W2002815709 @default.
• W2011841487 cites W2017569709 @default.
• W2011841487 cites W2019234680 @default.
• W2011841487 cites W2027542963 @default.
• W2011841487 cites W2029883816 @default.
• W2011841487 cites W2030094610 @default.
• W2011841487 cites W2036172367 @default.
• W2011841487 cites W2038417739 @default.
• W2011841487 cites W2039123138 @default.
• W2011841487 cites W2041666177 @default.
• W2011841487 cites W2046833247 @default.
• W2011841487 cites W2047104647 @default.
• W2011841487 cites W2061616084 @default.
• W2011841487 cites W2069695308 @default.
• W2011841487 cites W2080445657 @default.
• W2011841487 cites W2082511916 @default.
• W2011841487 cites W2085881821 @default.
• W2011841487 cites W2088719505 @default.
• W2011841487 cites W2095442833 @default.
• W2011841487 cites W2098047267 @default.
• W2011841487 cites W2101312385 @default.
• W2011841487 cites W2107298907 @default.
• W2011841487 cites W2115847666 @default.
• W2011841487 cites W2119277399 @default.
• W2011841487 cites W2142874979 @default.
• W2011841487 cites W2143693221 @default.
• W2011841487 cites W2144536924 @default.
• W2011841487 cites W2156198002 @default.
• W2011841487 cites W2166573361 @default.
• W2011841487 cites W2253501189 @default.
• W2011841487 doi "https://doi.org/10.1186/s12951-015-0082-8" @default.
• W2011841487 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4409778" @default.
• W2011841487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25890381" @default.
• W2011841487 hasPublicationYear "2015" @default.
• W2011841487 type Work @default.
• W2011841487 sameAs 2011841487 @default.
• W2011841487 citedByCount "83" @default.
• W2011841487 countsByYear W20118414872015 @default.
• W2011841487 countsByYear W20118414872016 @default.
• W2011841487 countsByYear W20118414872017 @default.
• W2011841487 countsByYear W20118414872018 @default.
• W2011841487 countsByYear W20118414872019 @default.
• W2011841487 countsByYear W20118414872020 @default.
• W2011841487 countsByYear W20118414872021 @default.
• W2011841487 countsByYear W20118414872022 @default.
• W2011841487 countsByYear W20118414872023 @default.
• W2011841487 crossrefType "journal-article" @default.
• W2011841487 hasAuthorship W2011841487A5016059121 @default.
• W2011841487 hasAuthorship W2011841487A5039142646 @default.
• W2011841487 hasAuthorship W2011841487A5062094407 @default.
• W2011841487 hasAuthorship W2011841487A5083810235 @default.
• W2011841487 hasAuthorship W2011841487A5086401476 @default.
• W2011841487 hasBestOaLocation W20118414871 @default.
• W2011841487 hasConcept C121608353 @default.
• W2011841487 hasConcept C126322002 @default.
• W2011841487 hasConcept C150903083 @default.
• W2011841487 hasConcept C165616093 @default.
• W2011841487 hasConcept C167734588 @default.
• W2011841487 hasConcept C185592680 @default.
• W2011841487 hasConcept C202751555 @default.
• W2011841487 hasConcept C203014093 @default.
• W2011841487 hasConcept C207001950 @default.
• W2011841487 hasConcept C2777025900 @default.
• W2011841487 hasConcept C2780394083 @default.
• W2011841487 hasConcept C2780427987 @default.
• W2011841487 hasConcept C502942594 @default.
• W2011841487 hasConcept C55493867 @default.
• W2011841487 hasConcept C71924100 @default.
• W2011841487 hasConcept C86803240 @default.
• W2011841487 hasConcept C86807702 @default.
• W2011841487 hasConcept C96232424 @default.
• W2011841487 hasConcept C98274493 @default.
• W2011841487 hasConceptScore W2011841487C121608353 @default.
• W2011841487 hasConceptScore W2011841487C126322002 @default.
• W2011841487 hasConceptScore W2011841487C150903083 @default.
• W2011841487 hasConceptScore W2011841487C165616093 @default.

• next